Literature DB >> 9488524

Albumin synthesis rates are not decreased in hypoalbuminemic cachectic cancer patients with an ongoing acute-phase protein response.

K C Fearon1, J S Falconer, C Slater, D C McMillan, J A Ross, T Preston.   

Abstract

OBJECTIVE: To determine whether suppression of albumin synthesis contributes to the hypoalbuminemia observed in weight-losing cancer patients with evidence of an ongoing acute-phase protein response (APPR). BACKGROUND DATA: Proinflammatory cytokines such as tumor necrosis factor (TNF) and interleukin 6 (IL-6) are known to downregulate albumin synthesis and increase acute-phase protein production in isolated hepatocytes. However, whether albumin synthesis is suppressed in hypoalbuminemic cancer patients with evidence of an ongoing acute-phase response is unknown.
METHODS: Albumin synthesis rates were determined in six healthy controls and in six weight-losing pancreatic cancer patients with an ongoing APPR using a flooding dose technique with [2H5]-phenylalanine. The presence of an APPR was defined as a serum C-reactive protein concentration >10 mg/L. Serum cytokines (TNF, IL-6) and soluble TNF receptors (sTNF-R 55 and 75), along with serum cortisol and insulin, were also measured in both groups.
RESULTS: Cancer patients had reduced serum albumin (median 32 [range, 23-36] vs. 42 g/L [40-45]; p < 0.01) and increased serum C-reactive protein concentrations (72 [23-126] vs. <5 mg/L; p < 0.01) when compared with controls. TNF was not detected in either group. sTNF-R 55 levels were significantly elevated in the cancer patients (3.8 [1.9-8.1] vs. 1.2 pg/mL [0.9-2.2]; p < 0.01). Circulating IL-6, insulin, and cortisol concentrations were not significantly different between the groups. The intravascular albumin mass was lower (88 [56-93] vs. 133 g [105-177]; p < 0.01), but the intravascular albumin fractional synthetic rate was higher (13.9 [13.5-18.5] vs. 10.3%/d [71-11.3]; p < 0.01) in the cancer patients compared with the controls. The total intravascular albumin synthetic rate was, however, similar between the two groups (12.7 [7.7-15.7] vs. 11.7 g/d [8.5-18.7]; p NS).
CONCLUSIONS: In weight-losing pancreatic cancer patients with evidence of an ongoing APPR, hypoalbuminemia is not caused by a decreased rate of albumin synthesis.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9488524      PMCID: PMC1191243          DOI: 10.1097/00000658-199802000-00015

Source DB:  PubMed          Journal:  Ann Surg        ISSN: 0003-4932            Impact factor:   12.969


  26 in total

1.  Solubility of albumin in alcohol after precipitation by trichloroacetic acid: a simplified procedure for separation of albumin.

Authors:  J R DEBRO; A KORNER
Journal:  Nature       Date:  1956-11-10       Impact factor: 49.962

2.  Reversible inhibition of albumin production by rat hepatocytes maintained on a laminin-rich gel (Engelbreth-Holm-Swarm) in response to secretory products of Kupffer cells and cytokines.

Authors:  P W Kowalski-Saunders; P J Winwood; M J Arthur; R Wright
Journal:  Hepatology       Date:  1992-09       Impact factor: 17.425

3.  Sodium dodecyl sulfate-glycerol polyacrylamide slab gel electrophoresis for the resolution of apolipoproteins.

Authors:  G F Maguire; M Lee; P W Connelly
Journal:  J Lipid Res       Date:  1989-05       Impact factor: 5.922

Review 4.  Albumin synthesis (second of two parts).

Authors:  M A Rothschild; M Oratz; S S Schreiber
Journal:  N Engl J Med       Date:  1972-04-13       Impact factor: 91.245

5.  Insulin and counterregulatory hormones influence acute-phase protein production in human hepatocytes.

Authors:  M G O'Riordain; J A Ross; K C Fearon; J Maingay; M Farouk; O J Garden; D C Carter
Journal:  Am J Physiol       Date:  1995-08

6.  Tumor necrosis factor-alpha inhibits albumin gene expression in a murine model of cachexia.

Authors:  D A Brenner; M Buck; S P Feitelberg; M Chojkier
Journal:  J Clin Invest       Date:  1990-01       Impact factor: 14.808

7.  Effects of tumor necrosis factor-alpha on glucose and albumin production in primary cultures of rat hepatocytes.

Authors:  M S Dahn; C J Hsu; M P Lange; L S Jefferson
Journal:  Metabolism       Date:  1994-04       Impact factor: 8.694

8.  Mechanisms of experimental cancer cachexia. Local involvement of IL-1 in colon-26 tumor.

Authors:  G Strassmann; Y Masui; R Chizzonite; M Fong
Journal:  J Immunol       Date:  1993-03-15       Impact factor: 5.422

9.  Cytokines, the acute-phase response, and resting energy expenditure in cachectic patients with pancreatic cancer.

Authors:  J S Falconer; K C Fearon; C E Plester; J A Ross; D C Carter
Journal:  Ann Surg       Date:  1994-04       Impact factor: 12.969

10.  Tumor necrosis factor soluble receptors circulate during experimental and clinical inflammation and can protect against excessive tumor necrosis factor alpha in vitro and in vivo.

Authors:  K J Van Zee; T Kohno; E Fischer; C S Rock; L L Moldawer; S F Lowry
Journal:  Proc Natl Acad Sci U S A       Date:  1992-06-01       Impact factor: 11.205

View more
  35 in total

1.  Albumin synthesis rates in cachectic cancer patients with an ongoing acute-phase protein response.

Authors:  G Stehle; A Wunder; G Hartung; H Sinn
Journal:  Ann Surg       Date:  1998-11       Impact factor: 12.969

2.  Evaluation of covariate effects on pharmacokinetics of monoclonal antibodies in oncology.

Authors:  Gaurav Bajaj; Satyendra Suryawanshi; Amit Roy; Manish Gupta
Journal:  Br J Clin Pharmacol       Date:  2019-07-17       Impact factor: 4.335

3.  Impact of cachexia on pharmacokinetic disposition of and clinical responses to oxycodone in cancer patients.

Authors:  Takafumi Naito; Masaki Tashiro; Keisuke Yamamoto; Kazunori Ohnishi; Yoshiyuki Kagawa; Junichi Kawakami
Journal:  Eur J Clin Pharmacol       Date:  2012-03-23       Impact factor: 2.953

4.  Maintenance of the nutritional prognostic index predicts survival in patients with unresectable metastatic colorectal cancer.

Authors:  Tetsuro Ikeya; Masatsune Shibutani; Kiyoshi Maeda; Kenji Sugano; Hisashi Nagahara; Hiroshi Ohtani; Kosei Hirakawa
Journal:  J Cancer Res Clin Oncol       Date:  2014-08-15       Impact factor: 4.553

5.  Effect of internal biliary drainage on plasma levels of endotoxin, cytokines, and C-reactive protein in patients with obstructive jaundice.

Authors:  Francisco J Padillo; Jordi Muntane; Jose L Montero; Javier Briceño; Gonzalo Miño; Guillermo Solorzano; Antonio Sitges-Serra; Carlos Pera-Madrazo
Journal:  World J Surg       Date:  2002-09-26       Impact factor: 3.352

Review 6.  Updated Clinical Pharmacokinetics and Pharmacodynamics of Oxycodone.

Authors:  Mari Kinnunen; Panu Piirainen; Hannu Kokki; Pauliina Lammi; Merja Kokki
Journal:  Clin Pharmacokinet       Date:  2019-06       Impact factor: 6.447

7.  The value of the pretreatment albumin/globulin ratio in predicting the long-term survival in colorectal cancer.

Authors:  Basem Azab; Shiksha Kedia; Neeraj Shah; Steven Vonfrolio; William Lu; Ali Naboush; Farhan Mohammed; Scott W Bloom
Journal:  Int J Colorectal Dis       Date:  2013-07-16       Impact factor: 2.571

8.  Dynamics of albumin synthetic response to intra-abdominal abscess in patients with gastrointestinal fistula.

Authors:  Bo Zhou; Jianan Ren; Gang Han; Yu Chen; Jiye A; Guosheng Gu; Jun Chen; Gefei Wang; Jieshou Li
Journal:  Surg Infect (Larchmt)       Date:  2014-01-24       Impact factor: 2.150

9.  Co-culture of primary rat hepatocytes with rat liver epithelial cells enhances interleukin-6-induced acute-phase protein response.

Authors:  Stephan J A C Peters; Tamara Vanhaecke; Peggy Papeleu; Vera Rogiers; Henk P Haagsman; Klaske van Norren
Journal:  Cell Tissue Res       Date:  2010-04-22       Impact factor: 5.249

Review 10.  Hypoalbuminemia in colorectal cancer prognosis: Nutritional marker or inflammatory surrogate?

Authors:  Bassel Nazha; Elias Moussaly; Mazen Zaarour; Chanudi Weerasinghe; Basem Azab
Journal:  World J Gastrointest Surg       Date:  2015-12-27
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.